Immune checkpoint inhibitors in resectable gastroesophageal cancers - a review
Sign Up to like & getrecommendations! Published in 2022 at "Therapeutic Advances in Medical Oncology"
DOI: 10.1177/17588359221139625
Abstract: Gastroesophageal cancers (GEC) have a poor survival rate of 20–30% at 5 years, often due to delayed presentations. Neoadjuvant chemoradiotherapy (CRT) followed by surgery or peri-operative chemotherapy and surgery are widely used as the standard of… read more here.
Keywords: gec; resectable gec; checkpoint inhibitors; immune checkpoint ... See more keywords